Arbutus Biopharma Corporation
NASDAQ:ABUS · NASDAQ Global Select
+$0.05 today
Vol 4.94M · Avg 1.76M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+33.43%
Period High
$4.95
Period Low
$3.09
Latest
$4.55
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.51B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.58B
GH Research PLC
NASDAQ:GHRS
$1.48B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Savara Inc.
NASDAQ:SVRA
$1.11B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$951.33M
Kura Oncology, Inc.
NASDAQ:KURA
$857.03M
ProKidney Corp.
NASDAQ:PROK
$261.85M
What is the latest ABUS filing?
The latest filing shown is 4 dated Jun 10, 2026.
How many recent filings does ABUS have?
Intrinsic Alpha currently shows 20 recent filings for ABUS.
Explore More
Continue the stock analysis
Jump to another research area for this company.